UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 210

Sortiert nach

Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer

Annals of oncology, 2009-07, Vol.20 (7), p.1185-1192

2009

Volltextzugriff (PDF)

A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study

Annals of oncology, 2013-11, Vol.24 (11), p.2753-2760

2013

Volltextzugriff (PDF)

Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy

Annals of oncology, 2005-03, Vol.16 (3), p.383-388

2005

Volltextzugriff (PDF)

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer

JNCI : Journal of the National Cancer Institute, 1999-11, Vol.91 (21), p.1847-1856

1999

Volltextzugriff (PDF)

12. Is metabolic syndrome-breast cancer link relatable to specific molecular subtype?

European journal of surgical oncology, 2014-11, Vol.40 (11), p.S14-S14

2014

Volltextzugriff (PDF)

Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women

JNCI : Journal of the National Cancer Institute, 2003-01, Vol.95 (2), p.160-165

2003

Volltextzugriff (PDF)

149 Insulin Resistance, Metabolic Syndrome and Breast Cancer Risk -National Cancer Institute of Naples Experience

European journal of cancer (1990), 2012-03, Vol.48, p.S83-S83

2012

Volltextzugriff (PDF)

P127 Metabolic syndrome and breast cancer risk by molecular subtype

Breast (Edinburgh), 2015-03, Vol.24, p.S68-S68

2015

Volltextzugriff (PDF)

PR24 Difference of clinical features and molecular subtypes between under-forty and post-menopausal breast cancer patients in southern Italy

Breast (Edinburgh), 2014-11, Vol.23, p.S9-S10

2014

Volltextzugriff (PDF)

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer

Journal of clinical oncology, 1998-05, Vol.16 (5), p.1677-1683

1998

Volltextzugriff (PDF)

High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3083-3092

2013

Volltextzugriff (PDF)

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer : final analysis of a sicog phase III study

British journal of cancer, 2006-10, Vol.95 (8), p.1005-1012

2006

Volltextzugriff (PDF)

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908

Annals of oncology, 2010-04, Vol.21 (4), p.707-716

2010

Volltextzugriff (PDF)

P152 Metabolic syndrome: Breast cancer risk indicator in postmenopausal women

Breast (Edinburgh), 2011, Vol.20, p.S30-S31

2011

Volltextzugriff (PDF)

Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort

Annals of oncology, 2012-07, Vol.23 (7), p.1838-1845

2012

Volltextzugriff (PDF)

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British journal of cancer, 2006-05, Vol.94 (9), p.1233-1236

2006

Volltextzugriff (PDF)

A 2-month cisplatin–epirubicin–paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study

Annals of oncology, 2005-08, Vol.16 (8), p.1268-1275

2005

Volltextzugriff (PDF)

Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy

JNCI : Journal of the National Cancer Institute, 2007-05, Vol.99 (9), p.727-737

2007

Volltextzugriff (PDF)

P11 Metabolic syndrome as modifiable risk factor in breast cancer

European journal of cancer supplements, 2010, Vol.8 (2), p.14-14

2010

Volltextzugriff (PDF)

An assessment of delays in obtaining definitive breast cancer treatment in Southern Italy

Breast cancer research and treatment, 2001-04, Vol.66 (3), p.209-215

2001

Volltextzugriff (PDF)

P15 Genetic counseling in breast cancer. The National Cancer Institute of Naples experience

European journal of cancer supplements, 2008, Vol.6 (3), p.46-46

2008

Volltextzugriff (PDF)

Re: delay in breast cancer: a prevention dilemma

Preventive medicine, 2002-12, Vol.35 (6), p.616-617

2002

Volltextzugriff (PDF)

Genetic counseling in breast cancerThe National Cancer Institute of Naples experience

European journal of cancer supplements, 2008, Vol.6 (7), p.74-74

2008

Volltextzugriff (PDF)

Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study

Annals of oncology, 2000-03, Vol.11 (3), p.367-371

2000

Volltextzugriff (PDF)

Radiofrequency ablation in patients with primary breast carcinoma : a pilot study in 26 patients

Cancer, 2001-10, Vol.92 (8), p.2036-2044

2001

Volltextzugriff (PDF)

1 – 25 von 210

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(186)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer

A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study

Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer

12. Is metabolic syndrome-breast cancer link relatable to specific molecular subtype?

Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women

149 Insulin Resistance, Metabolic Syndrome and Breast Cancer Risk -National Cancer Institute of Naples Experience

P127 Metabolic syndrome and breast cancer risk by molecular subtype

PR24 Difference of clinical features and molecular subtypes between under-forty and post-menopausal breast cancer patients in southern Italy

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer

High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer : final analysis of a sicog phase III study

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908

P152 Metabolic syndrome: Breast cancer risk indicator in postmenopausal women

Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

A 2-month cisplatin–epirubicin–paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study

Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy

P11 Metabolic syndrome as modifiable risk factor in breast cancer

An assessment of delays in obtaining definitive breast cancer treatment in Southern Italy

P15 Genetic counseling in breast cancer. The National Cancer Institute of Naples experience

Re: delay in breast cancer: a prevention dilemma

Genetic counseling in breast cancerThe National Cancer Institute of Naples experience

Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study

Radiofrequency ablation in patients with primary breast carcinoma : a pilot study in 26 patients

Suchergebnisse filtern